X
Based in the UK, Bioven has offices in Aberdeen and Kuala Lumpur
OUR STORY OUR TEAM
Bioven was founded in 2002 in Kuala Lumpur, Malaysia. Since 2008 it has focused on the development of novel treatments for cancer and has attracted an experienced management team with a depth of knowledge and experience gained at major pharmaceutical companies. It has also developed an international network of academic, medical and clinical collaborators.

Bioven secured multi-territorial rights to a novel immunotherapy, EGF PTI, from the Centre for Molecular Immunology based in Havana, Cuba. Considerable clinical data had already been generated in Cuba in non-small cell lung cancer, indicating a significant overall survival benefit with low toxicity.

Bioven carried out further development work on EGF PTI and this is now in a global, biomarker Phase III trial. In addition to regulatory approvals in Europe, Bioven obtained FDA and OFAC approval in Dec 2016

Bioven set up an R&D centre in Aberdeen, Scotland and collaborates with the best research institutes and CRO’s across Europe. From 2012, Bioven has developed a portfolio of potential cancer compounds. It is committed to the highest standards of trial design to advance the compounds through the changing environment of the cancer drug development process.
OUR STRATEGY
Bioven's therapeutic focus is on solid tumour cancer.
Bioven's strategy is to develop it's own and/or to in-license compounds at a pre-clinical or clinical stage and then to use the company's core skills to develop the compounds through PDX and GEMM modelling and as necessary through to late-stage clinical trials. Its commercialisation strategy is to out-license compounds in development to global or specialty pharmaceutical companies.
Bioven's strategy is underpinned by ownership of robust global intellectual property rights. A team of UK and US based IP lawyers assure protection for the commercialization of said compounds.

Bioven intends to advance its compounds to Phase I and Phase II clinical trials based on the mild safety profile clinical data and potential comparable overall survival benefit.